Uroplasty, Inc. operates in the Surgical and medical instruments sector. Uroplasty, Inc. is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions. The Company's primary focus is on two products: the Urgent PC system and Macroplastique. The Urgent PC system is a United States Food and Drug Administration (FDA)-approved minimally invasive, office-based neuromodulation therapy for the treatment of urinary urgency, urinary frequency and urge incontinence that are symptoms often associated with overactive bladder (OAB). Macroplastique is a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency (ISD). Outside of the United States, the Company's Urgent PC is also approved for treatment of fecal incontinence, and Macroplastique is also approved for treatment of male stress incontinence and vesicoureteral reflux. In our complete report available for purchase the company is compared to: Cytori Therapeutics, Inc., NMT Medical, Inc. and United American Healthcare Corporation.